Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.

RMD Open · 2022 · PMC9114845 · PMID 35577477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In unadjusted analyses, the proportions of patients with radiographic non-progression at months 12 and 24 (based on patients pooled from ORAL Scan and ORAL Start studies) showed a trend towards higher rates of non-progression with higher baseline BMI in patients treated with tofacitinib 10 mg twice daily ( online supplemental figure 5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.